Case Report Of PD-L1 Monoclonal Antibody For Treating Advanced Lung Adenocarcinoma

In recent years,with the high fatality rate and low 5-year survival rate of lung cancer,it have been brought our more attention.In our country,the incidence of lung cancer in male malignant tumors is in the first place and the second place in women.And about 80%-85% patients of lung cancer pathological types are small cell lung cancer(NSCLC),The morbidity and mortality of NSCLC has risen to the first place.Currently limited intervention makes the poor prognosis of patients with lung cancer,how to improve the effect of the treatment of patients with non-small cell lung cancer is a major challenge for the clinical.In addition to the traditional surgery,radiotherapy,chemotherapy and targeted therapy,with the deepening development of mechanism and treatment therapy of lung cancer,molecular immune therapy has become the new direction in the study of lung cancer treatment.To consider programmed death receptor 1(PD-1)/programmed death ligand,(PD-L1)as the representative for the immune checkpoints molecules play an important role in non-small-cell lung cancer(NSCLC).Researches confirm PD-1 inhibitors--its monoclonal antibody resistance the survival in patients of advanced non-small cell lung cancer,and the PD-L1 latent capacity in curative effect as biomarkers.In 2015,the United States food and drug administration(FDA)approved PD-1 monoclonal antibody Nivolumab and Pembrolizumab treat advanced non-small cell lung cancer,and PD-L1 monoclonal antibody Atezolizumab followed close approved by the FDA for the treatment of advanced non-small cell lung cancer in October 2016.Thus it can be seen that the PD-1 /PD-L1 therapy research on the non-small cell lung cancer work on rapidly.This paper reports one of PD-L1 monoclonal antibody Atezolizumab therapy of elderly male patients with advanced lung adenocarcinoma cases in our hospital.